Spectral Medical (TSE:EDT) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Spectral Medical Inc. has announced significant progress in their Tigris trial for the treatment of septic shock, with 132 patients enrolled as of September 2024 and nearing the target enrollment for the study’s completion by year end. The company is advancing a novel therapeutic device, PMX, which has shown promise in treating septic shock and is seeking FDA approval.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
